Statistical Analysis Dichotomous outcomes were analyzed by risk ratios (RRs) and 95% confidence intervals (CIs) using the DerSimonian and Laird random-effects model
There are risks to the mother and fetus associated with poorly controlled diabetes in pregnancy (see Clinical Considerations )
Retatrutide TRIUMPH-1 (2023) and TRIUMPH-2 (2024) TRIUMPH-1 (Jastreboff et al., NEJM 2023): 338 non-diabetic adults with obesity, 48 weeks at escalating doses: 12 mg dose: 24.2% weight loss 8 mg dose: 22.8% 4 mg dose: 17.5% Placebo: 2.1% TRIUMPH-2 (Rosenstock et al., Lancet 2024) confirmed effects in T2D patients with concurrent NAFLD improvement (hepatic fat reduction 54% at 24 weeks, 12 mg dose)
Genetic variants in the GLP1-related genes are linked to obesity and diabetes
Some practical considerations: Evening injection some patients prefer injecting in the evening so they can sleep through any initial side effects like nausea Consistency matters most choosing the same day and roughly the same time each week helps maintain stable drug levels Injection sites abdomen, thigh, or upper arm, with rotation between sites to reduce injection-site reactions What about non-standard intervals (every 5 days)
